Alx Oncology Holdings  (ALXO)

Currency in USD
0.70
+0.04(+6.05%)
Closed·
After Hours
0.700.00(-0.01%)
·
ALXO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
ALXO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.660.72
52 wk Range
0.402.79
Key Statistics
Prev. Close
0.66
Open
0.66
Day's Range
0.66-0.72
52 wk Range
0.4-2.79
Volume
697.89K
Average Volume (3m)
546.77K
1-Year Change
-74.55%
Book Value / Share
1.65
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALXO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.25
Upside
+221.43%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Alx Oncology Holdings  News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Alx Oncology Holdings  Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Compare ALXO to Peers and Sector

Metrics to compare
ALXO
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.8x−0.5x
PEG Ratio
−0.01−0.030.00
Price/Book
0.4x2.5x2.6x
Price / LTM Sales
-154.2x3.3x
Upside (Analyst Target)
278.8%205.9%43.5%
Fair Value Upside
Unlock0.0%6.9%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.25
(+221.43% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.58 / -0.52
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ALXO Income Statement

People Also Watch

0.413
ADIL
-4.84%
16.26
SRPT
-2.93%
0.04
GIBO
-19.23%
0.561
WINT
+5.45%
6.720
BBAI
-4.55%

FAQ

What Stock Exchange Does Alx Oncology Trade On?

Alx Oncology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Alx Oncology?

The stock symbol for Alx Oncology is "ALXO."

What Is the Alx Oncology Market Cap?

As of today, Alx Oncology market cap is 37.46M.

What Is Alx Oncology's Earnings Per Share (TTM)?

The Alx Oncology EPS (TTM) is -2.45.

When Is the Next Alx Oncology Earnings Date?

Alx Oncology will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is ALXO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alx Oncology Stock Split?

Alx Oncology has split 0 times.

How Many Employees Does Alx Oncology Have?

Alx Oncology has 65 employees.

What is the current trading status of Alx Oncology (ALXO)?

As of 07 Aug 2025, Alx Oncology (ALXO) is trading at a price of 0.70, with a previous close of 0.66. The stock has fluctuated within a day range of 0.66 to 0.72, while its 52-week range spans from 0.40 to 2.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.